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Abstract: Streptococcus pneumoniae is a major pathogen causing pneumonia with over 2 million
deaths annually, especially in young children and the elderly. To date, at least 98 different
pneumococcal capsular serotypes have been identified. Currently, the vaccines for prevention
of S. pneumoniae infections are the 23-valent pneumococcal polysaccharide-based vaccine (PPV23)
and the pneumococcal conjugate vaccines (PCV10 and PCV13). These vaccines only cover some
pneumococcal serotypes and are unable to protect against non-vaccine serotypes and unencapsulated S.
pneumoniae. This has led to a rapid increase in antibiotic-resistant non-vaccine serotypes. Hence, there
is an urgent need to develop new, effective, and affordable pneumococcal vaccines, which could cover
a wide range of serotypes. This review discusses the new approaches to develop effective vaccines
with broad serotype coverage as well as recent development of promising pneumococcal vaccines in
clinical trials. New vaccine candidates are the inactivated whole-cell vaccine strain (∆pep27∆comD
mutant) constructed by mutations of specific genes and several protein-based S. pneumoniae vaccines
using conserved pneumococcal antigens, such as lipoprotein and surface-exposed protein (PspA).
Among the vaccines in Phase 3 clinical trials are the pneumococcal conjugate vaccines, PCV-15
(V114) and 20vPnC. The inactivated whole-cell and several protein-based vaccines are either in
Phase 1 or 2 trials. Furthermore, the recent progress of nanoparticles that play important roles as
delivery systems and adjuvants to improve the performance, as well as the immunogenicity of the
nanovaccines, are reviewed.
Keywords: Streptococcus pneumoniae; vaccines; live attenuated vaccine; pneumococcal surface-exposed
protein; nanoparticle; bacterium-like particle
1. Introduction
Streptococcus pneumoniae or pneumococcus is a common human pathogen contributing to significant
morbidity and mortality annually, especially in children, the elderly, and the immunocompromised [1].
S. pneumoniae remains the leading cause of community-acquired pneumonia (CAP) despite the
worldwide administration of pneumococcal vaccines [2]. S. pneumoniae can also cause a myriad of
non-invasive and invasive diseases. Non-invasive pneumococcal diseases include sinusitis, acute
otitis media, and pneumonia that is localized to the lungs [3,4]. The invasive form of pneumococcal
pneumonia can lead to bacteremia and meningitis [3]. In the US, pneumococcal sepsis and meningitis
contributed to a few thousand deaths annually in adults. The pneumococcus normally colonizes
the nasopharynx asymptomatically and colonized humans serve as an effective reservoir for the
pneumococcus, facilitating the transmission of the bacteria in the community [3,5]. There are at least
98 serotypes of pneumococcus circulating worldwide, categorized according to the unique glycan
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components and linkages that constitute the capsular polysaccharide of each serotype [6]. However,
the 10 most common types cause 62% of invasive disease worldwide [7].
2. Current Pneumococcal Vaccines in the Market
There are two types of pneumococcal vaccines that are available in the market: Pneumovax23 or
23-valent pneumococcal polysaccharide-based vaccine (PPV23) and Pneumococcal conjugate vaccines
(PCVs). Pneumovax23 (PPV23) was licensed in 1983 and is distributed by Merck (Lansdale, PA, USA).
This polysaccharide vaccine was manufactured by purifying the capsular polysaccharide antigens
from 23 different serotypes of the pneumococcus [8]. These 23 serotypes are responsible for 85–90% of
invasive pneumococcal infections in the world. PPV23 is recommended for individuals aged 65 years
and above as well as individuals aged 2 to 64 who had comorbidity, such as chronic cardiovascular
disease and diabetes [9]. The effectiveness of PPV23 appeared to be dependent on whether the
measured outcome is due to the incidence of invasive or non-invasive pneumococcal diseases. Studies
showed the vaccine could only lessen the severity of CAP but not prevent it, and it could not reduce the
incidence of non-invasive pneumonia and morbidity [10,11]. This is likely due to PPV23, which could
only elicit serum IgG but not secretory IgA in the nasopharynx [12]. However, PPV23 is thought to be
effective in preventing invasive pneumococcal disease (IPD) in healthy individuals under 75 years [13].
It is widely accepted that PPV23 is not effective in children due to the inability of the vaccine to generate
immunological memory [14,15] and the vaccine also did not lead to reduced carriage [16].
Pneumococcal conjugate vaccines (PCVs) were first introduced in 2000 in the form of PCV7.
The current PCVs in the market are Prevnar13, manufactured by Pfizer, and a relatively newer
10-valent pneumococcal non-typeable Haemophilus influenza protein D conjugate vaccine (PHiD-CV),
manufactured by GlaxoSmithKline plc. (Brentford, UK) [17]. PCV13 was formulated by conjugating
capsular polysaccharide antigens with the diphtheria toxoid carrier protein, CRM197 [18]. PHiD-CV
contained pneumococcal polysaccharides of eight serotypes conjugated to the non-typeable Haemophilus
influenza carrier protein D, serotype 18C conjugated to tetanus toxoid, and serotype 19F conjugated to
diphtheria toxoid, leading to a 10-valent vaccine [19]. Both vaccines include the serotypes causing the
majority of IPD in the world, including serotype 19A, which is the most common IPD-causing serotype
in young children [20,21]. PCV vaccines were able to confer better immunogenicity due to their ability
to elicit memory T cell response [22]. Therefore, younger infants are the target group for PCVs with a
dose that is advised to be given 2p + 1 (two primary doses before 6 months of age and one booster
dose at 9 months of age) or a 3p + 0 (three primary doses before 9 months of age without a booster
dose) schedule [23]. PCVs were reported to reduce pneumonia in children [24] and the vaccine did not
interfere with the immune responses to co-administer routine pediatric vaccines [25]. Herd immunity
was also achieved due to the ability of the PCVs to reduce carriage [26], which subsequently lowered
vaccine-type IPD and non-IPD cases in both vaccinated and unvaccinated individuals [27,28]. It is
worth noting that the vaccine effectiveness is contingent on the serotypes included in the vaccine
as the overall vaccine effectiveness of PCV13 was 33.2% {95% Confidence Interval(CI)—106.6% to
82%} against pneumococcal CAP irrespective of serotype and 38.1% (95% CI—131.9% to 89%) against
vaccine-type-CAP in the cohort of adults ≥ 65 years [29]. Unfortunately, the number of serotypes that
could be included in a PCV formulation could not be increased easily as the production of PCV is
complex and expensive [30].
The introduction of pneumococcal vaccines has increased the prevalence of pneumococcal disease
caused by the serotypes not included in the vaccine formulation [31]. This is referred to as serotype
replacement due to the greater diversity of serotypes in the developing countries. To date, there are
at least 98 serotypes of pneumococcus that have been identified [32,33]. With the implementation
of pneumococcal vaccines, the niches vacated by the vaccine serotypes tend to be colonized by
non-vaccine serotypes [34]. In a study of Alaska native children, invasive pneumococcal disease (IPD)
rates were found to have returned to pre-vaccine levels due to non-vaccine serotypes [35]. There is a
tendency for the non-vaccine serotypes to be highly invasive and possessing higher levels of antibiotic
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resistance [36,37]. PHiD-CV vaccination was associated with a delayed, relatively lower increase in
the non-vaccine-type carriage in clinical studies. However, the problem of serotype replacement still
existed and was not eliminated with the administration of PHiD-CV [38]. In addition, geographical
differences in serotype distribution have led to reduced effectiveness of the vaccines when they were
implemented in geographic areas where the serotypes were not covered by the vaccines [21].
The propensity of S. pneumoniae to acquire new genetic materials via natural transformation
and recombination makes it one of the deadly human pathogens. This enables the pneumococcus
to evolve according to the host environment [39]. Pneumococcus is known to undergo frequent
recombination [40,41]. Capsule switching was reported to occur more often following the introduction
of pneumococcal vaccines [42]. Moreover, mutations that disrupted the loci, which encoded for
capsular polysaccharide biosynthesis, could lead to the emergence of unencapsulated, non-typeable
pneumococcus [43]. The pneumococcal surface protein K in these bacterial variants has been suggested
to assist in adhesion, contributing to 3–19% of pneumococcal diseases [44]. Acute otitis media caused
by non-invasive and non-fatal pneumococcus does exert a large economic burden as it is one of the
most common disorders requiring medical care for children [45,46]. Unfortunately, the prevention of
acute otitis media caused by serotypes included in PCV remained moderate to low [47,48]. PHiD-CV
was shown to be more effective in preventing acute otitis media than PCV7 [38,49].
3. Novel Strategies for the Development of New Vaccines against Streptococcus pneumoniae
Severe diseases caused by pneumococcus still occur despite the availability of the pneumococcal
polysaccharide (PPV23) and conjugate (PCV13) vaccines in the market. The fast spread of multidrug-
resistant strains has accelerated the global problem of pneumococcal diseases. The limitations posed
by the current PCV vaccines include high costs and insufficient serotype protection [12,50]. Although
the introduction of PPVs and PCVs have effectively reduced the disease burden, emerging new clinical
isolates require adding newer serotypes to vaccine formulations [51–53]. Considering that there are at
least 98 serotypes of pneumococcus, it would be more complex and expensive to increase the number of
vaccine serotypes in the PCV vaccine formulations. Hence, there is a need to develop new pneumococcal
vaccines. A pneumococcal vaccine that exhibits the potential to provide broad serotype coverage,
induce mucosal and systemic immunity, and hinder primary intranasal colonization, as well as invasive
disease, is much desired. Several pneumococcal proteins have been studied as vaccine candidates such
as the pneumococcal surface protein A (PspA) pneumolysin (Ply), pneumococcal surface protein C
(PspC), and pneumococcal surface adhesin A (PsaA), which have been comprehensively reviewed by
many researchers [54–57]. Here, we focus on highlighting new approaches to developing the whole-cell
vaccines, discovering new protein antigens or genetic manipulations of protein antigens to make more
effective vaccines for the next generation S. pneumoniae vaccines.
3.1. Protein-Based Vaccines
Pneumococcal virulence proteins that have well-conserved sequences and could confer broad
serotype coverage are desirable. They are less expensive than PCVs to manufacture. In the past, protein
vaccine developments were based on the antigens with known functions in bacterial pathogens, but
reverse vaccinology and ANTIGENome technology have contributed to the discovery of novel protein
antigens [58,59]. The highly conserved proteins with broad serotype coverage have been extensively
investigated as vaccine candidates are listed in Table 1.
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Table 1. Localization and function of Streptococcus pneumoniae virulence proteins that are well conserved
among different serotypes.
Protein Localization Function References
Pneumococcal surface
protein A (PspA) Surface protein
Inhibits complement-mediated clearance of
pneumococci [60–62]
Pneumococcal surface
protein C (PspC) Surface protein
Adhesin, interacts with human secretory
immunoglobulin A (IgA) and immunoglobulin
receptor (pIgR), inhibits complement activation by
interacting components C3 and factor H (FH) to
inhibit pneumococcus binding
[63,64]
Pneumolysin (Ply) Cytoplasm/Cell wall
Able to insert into eukaryotic cell membranes and
oligomerize to form large transmembrane pores
which lead to cell lysis
[65,66]
Pneumococcal histidine
triad protein D (PhtD) Surface protein Adhesin, high affinity to bind to Zinc ion [67]
Elongation factor Tu
(EF-Tu) Surface protein
Catalyzes the binding of an aminoacyl-tRNA
(aa-tRNA) to the ribosome. Inhibit protein synthesis [68]
Pneumococcal peptide 27
(Pep27) Cell membrane
Enable the bacteria to attach or colonize in the lungs,
blood, and brain [15]
Pneumococcal surface protein A (PspA) is a choline-binding protein present on the cell surface
of almost all pneumococcal strains. The N-terminal domain of PspA is exposed on the surface and
the sequence variations are used to classify pneumococcal strains into three families and six clades.
Almost 98% of clinical isolates are from families 1 (clades 1 and 2) and 2 (clades 3 to 5) [60]. PspA is
known to inhibit the complement-mediated clearance of pneumococci. The PspA vaccine was shown
to be cross-protective in animal models against multiple serotypes causing carriage and invasive
diseases [61,62,69]. Phase I clinical trials demonstrated the safety and ability to elicit strong antibody
responses in the murine model [70]. However, there is concern to use the whole PspA as it has
homology to the human cardiac myosin and could elicit autoantibodies that might promote cardiac
inflammation or autoimmune disease [71]. Therefore, novel strategies to develop the PspA-based
vaccine would focus on regions of the PspA that do not contain any homology with myosin.
The N-terminal domain of PspA has an α-helical coiled-coil structure and is divided into three
regions, A, B and C. The B region exhibits serological variability and is known as a clade-defining
region [72]. Akbari et al. constructed a recombinant PspA-based protein vaccine (PspAB1-5) comprising
the B region fragments from clades 1 to 5 of both families 1 and 2. In the mice immunized with
PspAB1-5, an increased in C3 complement component deposition on the pneumococcal surface was
found. The anti- PspAB1-5 antibodies showed cross-reactivity against pneumococci from clades 1, 2,
and 5. In addition, the PspAB1-5 vaccine was able to confer protection in immunized mice against a
S. pneumoniae strain from clade 2 in a challenge study. Therefore, the PspA-based vaccine derived from
the B region of all clades would be able to confer significant protection against multiple serotypes of S.
pneumoniae and could serve as key antigenic epitopes to overcome the limitations of the polysaccharide
and conjugated vaccines [73].
Besides the N-terminal α-helical domain, which is responsible for eliciting cross-protective
immunity, the proline-rich domain (PRD) in the center (~90 amino acids) of the PspA was able to
elicit protective antibodies against pneumococcal infection [74]. The diversity of the PRD sequence
from 123 pneumococcal isolates led to the recognition of the three PRD groups. Sera from 12 healthy
human adults showed antibodies to PRD fragments from pneumococcal strains belonging to each of
the three PRD groups. This suggested that a PspA-based vaccine should include conserved epitopes
from the PRD of each of the three groups and the α-helical highly charged domain. This approach
could provide broad coverage and reduced the likelihood of PspA variants to escape immunity [75].
Pneumococcal surface protein C (PspC) is a cell-wall associated surface protein that is a major
virulence factor in almost all pneumococci [76]. PspC plays an important role in bacterial adhesion,
invasion, and evasion of complement [77]. It functions as an adhesin by interacting with the secretory
component of immunoglobulin A (SIgA) and laminin-integrin receptors [78]. The ability of PspC to bind
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directly with complement component C3 and recruit factor H to the bacteria surface led to reduction
in complement activation. Several studies have demonstrated that PspC is highly immunogenic
and the anti-PspC antibodies were able to confer protection against carriage and challenge against
invasive disease in mice. Despite the presence of the PspC gene in almost all pneumococci, it is highly
polymorphic and PspC variants were found to differ in their capacity to bind factor H. It was reported
that a S. pneumoniae strain, which expressed a PspC variant matching the antibody specificity was
killed efficiently, but antibody was not effective against mismatched PspC variants [79]. Due to the
high diversity in the protein sequence of the PspC, the whole protein might not serve as an ideal
vaccine for cross-protective immunity.
Pneumolysin (Ply) is a cytotoxic cholesterol-binding protein, which is released during autolysis
of bacteria that can form pores in eukaryotic membranes [65,66]. Besides its lytic activity, Ply is able
to activate complement and the innate immune system through the toll-like receptor-4 (TLR4) and
NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome [80–82]. Activation of
complement by Ply is known to cause complement depletion and reduces complement binding to
pneumococcus. However, in non-immune mice and unvaccinated humans, C3 deposition was increased
in pneumococcus [83]. Non-toxic variants of Ply were found to produce much less inflammation in the
mouse lung [84]. It was reported that TLR4-deficient mice were more easily colonized and showed
higher susceptibility to sepsis [81].
The pneumococcal histidine triad proteins (Phts) are a family of surface proteins that have an
unusual polyhistidine motif, HXXhXH, which is repeated five or six times in their protein sequences.
Pneumococcal histidine triad protein D (PhtD) functions as an adhesin and has a high affinity for
zinc [67]. The high levels of zinc in the nasopharynx and lung facilitated the greater surface attachment
of pneumococcus. It is a highly conserved surface protein. The PhtD vaccines were able to protect the
immunized mice and primates against pneumococcal nasopharyngeal and lung colonization [85–88].
A recombinant PhtD-based protein vaccine constructed by Seiberling et al. was shown to be safe and
immunogenic in adults (18–50 years) in a Phase 1 clinical trial and the second booster was able to
increase the levels of anti-PhtD antibodies [89]. The human anti-PhtD antibodies were found to be
functional in mice and conferred passive protection [90].
Elongation factor Tu (EF-Tu) is a surface-accessible protein found in the bacterial cytoplasm
and culture supernatant. EF-Tu is among the most conserved and universally expressed factors in
S. pneumonia and other pathogenic bacteria such as Streptococcus pyogenes, Staphylococcus aureus, and
Pseudomonas aeruginosa. EF-Tu displays molecular chaperone activity and it is involved in peptide
biosynthesis, protein folding and cell response to stress [91]. Nagai et al. showed that S. pneumoniae
released EF-Tu through autolysis and this was followed by the induction of proinflammatory cytokines
in macrophages via the toll-like receptor 4 [68]. A recombinant vaccine was developed containing only
the EF-Tu protein of S. pneumoniae strain D39 against pneumococcal infection. EF-Tu was produced
intracellularly and was presented on the surface of different S. pneumoniae strains belonging to serotypes
3, 7F, 10A, 12F, 15A, and 19A. Immunization of mice with recombinant (r) EF-Tu showed significant
enhancement in the production of cytokines including IL-6, TNFα, IFN-γ, and IL-17. In addition, an
increased CD4+ T-cell population in splenocytes as well as IgG1 and IgG2a antibodies were observed
in murine models. The anti-EF-Tu serum showed an increase of phagocytic activity of the peritoneal
macrophages against S. pneumoniae, independent of their serotypes. The mice immunized with
recombinant EF-Tu were shown to be protected against lethal challenges with S. pneumoniae serotype
2 and the multidrug-resistant serotype 15A [92]. Hence, pneumococcal EF-Tu could be a potential
broad-spectrum antigen candidate for a new vaccine against common pneumococcal serotypes.
3.2. Whole-Cell Vaccines
Whole-cell vaccines are able to express all protein antigens without requiring purification of
individual proteins. Thus, it could serve as an economical alternative to current polysaccharide-based
vaccines in developing countries. Several studies showed that the killed whole-cell or live-attenuated
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vaccines from unencapsulated S. pneumonia were able to confer serotype-independent protection, both
humoral and cellular responses against multiple antigens in animals [93–97].
3.2.1. Killed Whole-Cell Vaccine
The idea of a live pneumococcal attenuated vaccine posing greater risks is due to the propensity
of S. pneumoniae. It can lyse the cells using the lytA-dependent mechanism and release the toxin
pneumolysin along with its genetic materials that could be taken up by neighboring pneumococcal
cells [98]. Therefore, an inactivated vaccine could be much safer than a live attenuated vaccine.
Malley et al. constructed a killed whole-cell vaccine (WCV) using the S. pneumonia strain RX1, which is
a capsule-negative mutant derived from a pneumococcus capsular serotype 2. The strain RX1 was
mutated by deleting an autolysin (lytA) and killed using ethanol [97]. LytA is a virulence factor
involved in autolysis and penicillin-induced lysis [99]. The vaccine was administered intranasally
with cholera toxin (CT) as an adjuvant. It was able to confer protection against nasal colonization
and invasive disease in immunized mice and rats against encapsulated serotypes 6B and 3 strains in
a challenge study [97]. Administration of the vaccine by using nontoxic adjuvants such as cholera
toxin binding subunit (CTB) was shown to significantly decrease the nasopharyngeal and middle ear
colonizations by serotypes 6B, 14, 23F in murine models [100]. Later, the pneumolysin (Ply) gene was
also knocked out in strain RX1 and substituted with pneumolysoid. Pneumolysoid is a derivative of
Ply that contains the toxin gene with 3-point mutations known to eliminate both cytolytic activity and
complement activation but maintains its TLR4 agonistic properties. Lu et al. replaced the entire lytA
gene with the kanamycin resistance gene to improve the yield by reducing the autolysis and named the
strain RM200 (RX1E PdT∆lytA) [101]. The beta-propiolactone inactivated RM200 whole-cell vaccine
strain (WCV) was shown to confer good protection against nasopharynx colonization against serotype
6B and activated interleukin-17 A (IL-17A) priming [101]. The preclinical study demonstrated that the
administration of the beta-propiolactone inactivated WCV with aluminum hydroxide as an adjuvant
could significantly induce the IgG titers and IL-17 response [102]. Therefore, the vaccine has been
progressed to be evaluated in clinical trials [103].
3.2.2. Live Attenuated Whole-Cell Vaccines
Kim et al. reported the development of a live attenuated whole-cell vaccine that could provide
serotype-independent protection. The S. pneumoniae D39 was attenuated by removal of the pep27 gene
(∆pep27) and this led to the inability of bacteria to attach or colonize the lungs, blood, and brain [96].
The study also revealed that long-lasting protection against heterologous strains was observed in mice
immunized with adjuvant-free intranasal∆pep27 pneumococcus [15]. Moreover, immunization with the
∆pep27 pneumococcus was able to confer protection against secondary pneumococcal infections [104].
However, during immunization, there is a possibility of reversion of the ∆pep27 pneumococcus to
the wild type phenotype. To enhance the safety of the vaccine, comD was also deleted as it plays
an important role in activating competence. The results showed that the reversion of the ∆pep27
pneumococcus was eliminated by the removal of the additional comD gene. Immunization of the mice
with the ∆pep27∆comD double mutant significantly increased the IgG titers against pneumococcus
serotype D39, which were 50-fold higher in IgG titers between the first and fourth immunizations.
Immunization with the ∆pep27∆comD mutant strain was found to elicit PspA-specific IgG. One week
after the fourth weekly immunization, challenge of the mice against serotypes D39 or 6B showed a
significant increase in the survival rate (>80%) when compared to the control group. The ∆pep27∆comD
strain immunization reduced the colonization levels regardless of the serotype and a non-typeable
strain (NCC1). Moreover, the safety of the double mutant strain in normal and immunocompromised
mice was confirmed, which indicated that the ∆pep27∆comD strain could be used as a safe and effective
vaccine against pneumococci [96].
Jang et al. also constructed a live attenuated vaccine strain by removing the prolipoprotein
diacylglycerol transferase (lgt) gene from the capsule of the pneumococcal strain TIGR4 (TIGR4∆lgt).
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The vaccine strain was able to exhibit protection against heterologous pneumococcal strains.
Attenuation of the encapsulated pneumococcal strain TIGR4 by the removal of the lgt gene resulted
in a reduction of virulence and inflammatory activities. A certain period of colonization of the
TIGR4∆lgt strain in the nasopharynx could induce strong mucosal IgA and IgG2b-dominant systemic
antibody responses, which showed cross-reactivity to different pneumococcal serotypes. In addition,
intranasal immunization of mice with TIGR4∆lgt conferred protection against pneumococcal challenge
with serotypes 2 (D39), 3(wu2), 6B, 9V, 19F, and 23F strains. The immunogenicity response showed
that TIGR4∆lgt could serve as an attractive broad-spectrum pneumococcal vaccine candidate [105].
S. pneumoniae serotype 1 is the dominant pathogen associated with invasive disease in sub-Saharan
Africa despite their low carriage in the healthy population [106]. Terra et al. constructed a serotype
1 strain 519/43 that carried a defined pneumolysin (Ply) mutation (519/43∆ply), which caused a loss
of its ability to lyse red blood cells. Upon intraperitoneal challenge of mice immunized with strain
519/43∆ply, there were fewer bacteria present in the blood but there was no complete protection from
pneumoniae. Thus, Ply in strain 519/43 might be a weak virulence determinant [107]. This is in contrast
to its presence in the killed whole-cell vaccine strain R200, which had its Ply gene being replaced with
pneumolysoid, which carried three mutations in the Ply gene [101].
4. Promising Pneumococcal Vaccines in Clinical Trials
There are a number of pneumococcal candidate vaccines under development. A comprehensive
list of the vaccine candidates and those in clinical trials were reviewed by Lagousi et al., Pichichero
and Kim et al. [55,57,108]. In this review, we will only discuss those that appear to have progressed
substantially and the potential to reach the market.
Merck Sharp & Dohme Corp. (Kenilworth, NJ, USA) is currently conducting Phase 3 clinical trials
investigating a new conjugate vaccine, PCV-15 (V114), in healthy infants (42 to 90 days) (ClinicalTrials.
gov Identifier: NCT03692871) and in healthy adults 50 years of age and above (ClinicalTrials.gov
Identifier: NCT03480763) as well as in adults 50 years of age and above with increased risks
(ClinicalTrials.gov Identifier: NCT03547167). The PCV-15 (V114) included the 13-valent PCV-13 plus
serotypes 22F and 33F [109]. In previous Phase 1 and 2 studies, PCV15 displayed acceptable safety
profiles and induced IgG and opsonophagocytic activity to all 15 vaccine serotypes at levels comparable
to PCV13 for 10 of the 13 shared serotypes in healthy infants (≥42 days to ≤89 days) [109] and adults
≥50 years of age [110].
Pfizer Inc. (New York, NY, USA) evaluated the 20-valent pneumococcal conjugate vaccine (20vPnC).
The 20vPnC vaccine includes the 13 serotypes from Prevnar 13 plus seven additional serotypes (8,
10A, 11A, 12F, 15B, 22F, and 33F) which are known to cause IPD [21,111–114] and meningitis [115,116].
The seven new serotypes are often associated with antibiotic resistance [114,117,118] and high
fatality [119–122]. The phase 1 clinical trial in healthy adults (18–49 years) induced substantial
functional (OPA) and IgG responses to all vaccine serotypes [123]. The promising Phase 2 clinical
trial data have progressed the 20vPnC vaccine to Phase 3. The Phase 3 clinical trials (NCT03828617,
NCT03835975, and NCT03760146) have been conducted in 6000 adults, which include populations of
vaccine-naïve adults and adults with prior pneumococcal vaccination. The safety and immunogenicity
findings were assayed by measuring antibodies associated with serotype-specific bacterial killing
[opsonophagocytic activity (OPA)] prior to vaccination [124].
S. pneumoniae killed whole-cell vaccine (WCV) has the capacity to confer broader protection
against S. pneumoniae as many of the antigens were presented in their native conformations and
would be exposed to the host immune system [102]. The WCV vaccine was manufactured at Walter
Reed Army Institute of Research (USA) from strain RM200 (RX1E PdT ∆lytA) and inactivated with
beta-propiolactone. The WCV vaccine was administered with aluminum hydroxide in healthy young
adults in a 3-vaccination series in a Phase 1 trial. The vaccine showed favorable safety, tolerability, and
immunogenicity profile [103]. A Phase 2 study was conducted by PATH (Seattle, WA, USA) to find the
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optimal dosage for WCV and was recently evaluated in a clinical trial in healthy young Kenyan adults
(18 to 45 years) and toddlers (12 to 15 months) (ClinicalTrials.gov Identifier: NCT02097472).
A novel pneumococcal vaccine, PnuBioVax, was constructed by mutating the pneumococcal
toxin, pneumolysin, of S. pneumoniae serotype 4 TIGR4 strain into a non-toxic form. The mutation
was constructed such that the immunogenicity of the toxin was preserved and acted as a potent
activator of the complement system [125], the toll-like receptor 4 [81] and CD4 T cell migration [126].
The genetically-modified bacteria were then subjected to heat stress, induced by a temperature shift from
30 ◦C to 37 ◦C to mimic the translocation of the bacteria from being a commensal in the nasopharynx
to a pathogen in sterile sites such as the lungs and blood. In theory, this process would upregulate and
enrich for the surface proteins (PspA, PsaA, PiuA and non-toxic pneumolysin) associated with disease
manifestations. This cocktail of proteins constituted the multi-antigen protein vaccine. In the preclinical
study, rabbit sera immunized with PnuBioVax showed the killing of the vaccine strainTIGR4, and
also serotype strains 6B, 19F, and 15B in an opsonophagocytic killing assay. Moreover, incubation of a
number of pneumococcal strains in the immunized sera led to agglutination of the bacteria, inhibition
of pneumolysin-mediated lysis of erythrocytes and reduced bacterial invasion of lung epithelial cells
in vitro [127,128]. Hence, PnuBioVax offers the potential for broad-based protection via multiple
mechanisms of action irrespective of serotypes. PnuBioVax had undergone a Phase 1 clinical trial
(ClinicalTrials.gov Identifier: NCT02572635) sponsored by ImmunoBiology Limited (UK) and it was
found to be safe and immunogenic in healthy adults (18-40 years) [128].
The protein-based vaccine, PPrV, is a trivalent protein vaccine carrying combined recombinant
proteins, PcpA, PhtD, and PlyD1. Previously, it was shown that vaccination with PPrV protected
mice against lethal pneumonia in an infant murine model [129]. Following that, a Phase 1 study was
conducted by Sanofi Pasteur (France) and PPrV was found to be safe and immunogenic in adults,
toddlers and infants [130]. The study has since proceeded to Phase 2 trial, which investigated the
vaccine reactogenicity, safety, and immunogenicity when co-administered with the existing PHiD-CV
vaccine. This form of combination therapy might also provide a broader range of protection against
pneumococcal diseases [131]. Vaccination with PHiD-CV/dPly/PhtD-30 in pneumococcal vaccine-naïve
children was well-tolerated and immunogenic [132]. PPrV did confer protection by macrophage-
and complement-dependent mechanisms [133] as well as by reducing pneumococcal adherence and
nasopharyngeal colonization [134].
Three recombinant avirulent PspA-protein based vaccines were constructed by researchers from
Arizona State University [135]. Parenteral immunization with PspA has been shown to be protective
in a lethal challenge study [136,137]. An oral route of vaccine administration for the pneumococcal
vaccine has also been explored. In a Phase 1 clinical study, the three recombinant avirulent Salmonella
Typhi (RASV) strains, each expressing PspA, were compared as live vaccines to evaluate the safety
and tolerability of a single oral dosage in adult subjects (ClinicalTrials.gov Identifier: NCT01033409).
Effective protection against secondary pneumococcal pneumonia was previously achieved by oral
vaccination with an attenuated Salmonella delivering the PspA antigen in mice [138]. Despite PspA
being known to be serologically variable, a common major histocompatibility complex (MHC-II) epitope
against PspA was identified based on in silico prediction and ex vivo screening. The epitope was shown
to be necessary for inducing interleukin-17 A (IL-17A) and it was associated with cross-protection [139].
Pneumolysin (Ply) and pneumococcal histidine triad protein D (PhtD), either administered alone
or in combination, were shown to protect the mice against lethal challenges, pneumococcal disease and
nasopharyngeal carriage (NPC) [86,140]. Clinical trials were conducted by GSK (Belgium) to evaluate
the safety, reactogenicity, and immunogenicity of different pneumococcal protein-based formulations
in adults, toddlers, and infants. In a Phase 1 study (Clinicaltrials.gov Identifier: NCT00707798), healthy
adults (18–40 years) received two doses of one of six different formulations containing pneumolysin
toxoid (dPly) or PhtD alone or a mixture of the two proteins (dPly and PhtD) or a combination
of dPly and PhtD with the 10-valent pneumococcal non-typeable Haemophilus influenza protein D
conjugate vaccine (PHiD-CV). The control group received a single dose of the 23-valent pneumococcal
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polysaccharide vaccine (23PPV; Pneumovax23TM, Sanofi Pasteur MSD). The results showed that the
vaccine formulations containing dPly and PhtD, either alone or combined with PHiD-CV, were well
tolerated and immunogenic [141]. In step one of phase 2, (Clinicaltrials.gov Identifier: NCT00985751),
toddlers (12–23 months) received one of four investigational vaccine formulations containing a mixture
of dPly and PhtD or in combination with PHiD-CV. Licensed PHiD-CV was used as a control [142].
All the vaccine formulations were well-tolerated and immunogenic upon administration as a two-dose
primary vaccination followed by a booster dose. In step two of Phase 2 (ClinicalTrials.gov identifier:
NCT01262872), the impact of two formulations of vaccines containing dPly and PhtD combined with
PHiD-CV were evaluated in infants (aged 8-10 weeks). The inclusion of pneumococcal proteins in
the PHiD-CV/ dPly/PhtD vaccine showed no impact on pneumococcal NPC prevalence, despite the
success of these vaccines in preclinical trials in adults and toddlers. This could be due to the different
immunization routes, differences in the adjuvant and/or initial immune status of mice versus infants.
However, the quantitative relationship between the impact of pneumococcal protein-based vaccines on
NPC prevalence versus pneumococcal disease in humans is yet to be defined, and no effect on carriage
does not preclude protection against disease [143].
5. Development of Pneumococcal Nanovaccines
Vaccines are commonly administered via intramuscular injection routes but they are poor inducers
of mucosal immunity through this route. Furthermore, antigens are usually poorly immunogenic and
they require a suitable adjuvant or delivery system to deliver them through the oral, nasal, or mucosal
routes in order to facilitate the enhancement of antigen uptake and prolong antigen availability. Thus,
the use of adjuvants and delivery vehicles are important for the development of effective vaccines.
The current microparticles and nanoparticles that have been used in Pneumococcal antigen delivery are
listed in Table 2.
Protein-based vaccine such as PspA is a promising candidate for the development of a universal
serotype-independent vaccine. The entrapment of the PspA antigen in polymeric particles such as
poly-lactic acid (PLA) and poly (glycerol adipate-co-ω-pentadecalactone) (PGA-co-PDL) was stable
and found to elicit robust IgG responses in mice and rats. The protein integrity and antigenicity of
PspA were reported to remain unchanged [144,145].
Rodrigues et al. developed PGA-co-PDL polymeric nanoparticles (NPs) adsorbed with PspA from
clade 4 of family 2 (PspA4Pro) within L-leucine microcarriers (nanocomposite microparticles-NCMPs)
for mucosal delivery targeting the lungs (NP/NCMP PspA4Pro). The anti-PspA4Pro IgG antibodies
were induced in serum and lungs of the immunized mice. Serum IgG exhibited good binding efficiency
towards intact bacteria that expressed PspA from clades 3, 4, and 5 of pneumococcus family 2. However,
no binding to bacteria expressing PspA from clades 1 and 2 of family 1 was detected. In addition,
immunizing the mucus membrane with NP/NCMP PspA4Pro was capable of inducing local and
systemic antibodies that conferred partial protection against pneumococcus family 2 alone [146].
Bacterium-like particles (BLPs) have the potential to serve as an immune stimulant in mucosal
vaccine applications. Wang et al. developed a novel PspA protein vaccine based on BLP delivery
system that could provide broad protection against pneumococcal pneumonia in mice [147]. The shape
and size of BLPs are similar to bacteria (between 0.5 to 5µm) and were made from the food-grade
bacterium Lactococcus lactis through simple hot acid treatment. BLPs could serve as a carrier for PspA
protein bound to their surface through interaction with the protein anchor (PA) of L. lactis. BLPs could
activate antigen-presenting cells and act as a potent immune stimulant for mucosal immunization [148].
Lu et al. combined PspA from families 1 and 2 into BLP-based pneumococcal vaccines so as to
confer broader protection [149]. They successfully showed induction of high levels of serum IgG and
mucosal specific IgA against challenge in the murine model. Immunization with the PspA-BLP vaccine
protected against lethal intranasal challenge with pneumococci from families 1 and 2 regardless of the
serotype [147,149].
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Chitosan is a non-toxic, biodegradable, biocompatible natural polysaccharide and it was approved
by the Food and Drug Administration (FDA) as a safe adjuvant and vaccine delivery system [150,151].
In addition, the chitosan formulation was able to improve the immunogenicity of a peptide-based
vaccine and induced an immune response mediated by IgG2a [152]. Chitosan-DNA nanoparticles
expressing PsaA pneumococcal vaccine was able to induce mucosal and systemic immune responses as
well as increasing the protection against pneumococcal nasopharyngeal colonization [153]. Furthermore,
Xu et al. used chitosan to deliver the PsaA protein vaccine to immunize BALB/c mice intranasally.
Levels of IFN-γ, IL-17A, and IL-4 as well as IgG and mucosal IgA were significantly enhanced. In an
intraperitoneal challenge with pneumococcus serotype 3 or serotype 14, the survival rate of mice
immunized with chitosan–PsaA nanoparticles was improved [154]. In another study by Haryono et al.,
the chitosan nanoparticles prepared by ionic gelation and dry method were mixed with the 13-valent
pneumococcal conjugate vaccine (PCV13; Prevnar®; Pfizer Inc., New York, NY, USA) as a PCV antigen
model. The mice immunized with the PCV co-delivered with chitosan nanoparticles were found to
significantly enhanced anti- Pn14PS (pneumococcal type 14 polysaccharide) IgG subclass antibodies
such as IgG1, IgG2a, IgG2b, and IgG3. The antibodies were at higher levels than when the Quil-A
adjuvant was used as a control co-delivery system [155].
Tada et al. showed that the cationic liposomes (DOTAP/DC-chol liposomes) were able to enhance
the delivery of PspA to nasal dendritic cells of mice and conferred complete protection against lethal
infection S. pneumoniae. The DOTAP/DC-chol liposomes could be a potential adjuvant for nasal delivery
of pneumococcal vaccines as liposomes are biocompatible and biodegradable in the human body.
In general, size, surface charge, and chemical composition of liposomes are important factors to be
taken into consideration in the development of liposomes as the delivery system. However, limited
studies of liposomes as an adjuvant in pneumococcal vaccine development have been published [156].
Nanoparticles have been shown to be efficient in vaccine delivery systems. Gold nanoparticles
(GNPs) are small with a diameter of 1 to 100 nm. Gold nanoparticles carrying 45% of tetrasaccharide
derived from the S. pneumonia type 14 capsular polysaccharide (Pn14PS) and 5% ovalbumin 323–339
peptide (OVA323–339) were able to elicit antibodies that promoted the phagocytosis of the pneumococcus.
Additionally, T-helper cell activation was promoted [157,158].
Polyanhydrides are nanoparticles that were formulated using random copolymers based on
1,8-bis-(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG), 1,6-bis-(p-carboxyphenoxy) hexane (CPH), and
sebacic acid (SA) which were able to show beneficial vaccine delivery and adjuvant properties.
In addition, hydrophobicity, and surface erosion characteristics of polyanhydrides helped to stabilize
labile proteins and protected them from denaturation by enzymatic cleavage and acidic degradation.
Polyanhydride nanoparticles when administrated as a single dose vaccine was able to prolong the
release of antigens that continued to drive the adaptive immune response [159,160]. Wagner-Muniz et al.
designed a PspA-based polyanhydride nanovaccine by fully encapsulating the protein within the
polyanhydride nanoparticles. The vaccine was stable at room temperature and immunization of mice
with a single dose of the nanovaccine presented significantly higher survival rates (87.5%), even with a
25-fold reduction in the antigen dose when challenged against S. pneumoniae (strain A66.1 clad 2 of
family 1). This comparison was in contrast to the control mice which were immunized with the soluble
PspA protein alone. The efficacy of the nanovaccine was stable even after dry storage for 60 days at
room temperature [161].
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Table 2. Microparticles and nanoparticles for Pneumococcal antigen delivery.
Nanoparticles Characteristics ofNanoparticles
Pneumococcal
Strains Used in
Challenge Studies
Antigen (s) Results References
Polylactide (PLA) 45 kDa, 2–8 µm n/a PspA
The entrapment of PspA in PLA particles was observed to be stable.
Polymer particles entrapping PspA elicited robust IgG responses in both
mice and in rats.
Protein integrity of antigen load in microparticles was maintained.
[144]
Poly(glycerol adipate-co-
ωpentadecalactone)
(PGA-co-PDL)
322.83 ± 4.25 nm
(with the
adsorption of
PspA4Pro)
n/a PspA4Pro(PspA clade 4)
Antigen PspA4Pro release from PGA-co-PDL nanoparticle was confirmed.
PspA4Pro antigenicity was retained and the functional epitopes of the
antigen were active in the formulation.
[145]
Nanocomposite
microparticles
(NP/NCMP)
~2 µm
EF3030 (serotype
19F, PspA1)
ATCC6303 (serotype
3, PspA5)
PspA4Pro (PspA clade
4, encompassing
mature N-terminal
region till proline-rich
region)
Anti-PspA4Pro IgG antibodies in serum and lungs were induced.
Binding analysis of serum IgG to intact bacteria revealed efficient binding
to bacteria expressing PspA from clades 3, 4, and 5 (family 2). However, no
binding to bacteria expressing PspA from clades 1 and 2 (family 1) was
observed.
Immunization with NP/NCMP PspA4Pro was unable to decrease the
bacterial load in the lungs following challenge with a serotype 19F strain
expressing PspA from clade 1 (PspA1).
Local and systemic antibodies were induced and offered protection against
only one strain expressing PspA in homologous family 2.
[146]
Bacterium-like particles
(BLP)
Similar to the size
of the
bacterium—0.5 to
5µm
ATCC6303 (PspA
family 2 clade 5,
serotype 3)
ATCC101813 (PspA
family 1 clade 2,
serotype 3)
PspA, family2 clade-4
(derived from
N-terminal α-helical
region and the
proline-rich region of
pneumococcal strain
EF5668
Safe and affordable.
Both PspA-specific IgG and PspA-specific IgA were induced.
Complete protection in a mouse challenge model (immunized with
BLPs/PspA-PA) with pneumococci from two different clades of both
homologous and heterologous PspA families that led to high protection
against challenges with heterologous pneumococci and showed broader
specificity.
[147]
ATCC6304 (PspA
family 1, clade 1)
ATCC10813 (PspA
family 1, clade 2)
ATCC6319 (PspA
family 2, clade 3)
ATCC6314 (PspA
family 2, clade 4)
ATCC6303 (PspA
family 2, clade 5)
PspA2 and PspA4
High levels of serum IgG and mucosal SIgA were induced.
Binding to pneumococcal strains expressing PspA from clades 1 to 5 was
observed.
Immunization with the PspA-BLP vaccine conferred protection against
fatal intranasal challenge with both PspA family 1 and family 2
pneumococcal strains.
[149]
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Table 2. Cont.
Nanoparticles Characteristics ofNanoparticles
Pneumococcal
Strains Used in
Challenge Studies
Antigen (s) Results References
Chitosan-DNA
Nanoparticles
The average size
of particle was 392
nm; zeta potential
was +12.5 mV
S. pneumoniae ATCC
6303 (serotype 3)
pVAX1-PsaA
(867-bp PsaA gene
was amplified from S.
pneumoniae genomic
DNA ATCC 6303;
serotype 3)
Anti-PsaA IgG antibody in serum and anti-IgA antibody in mucosal
lavages were increased.
Cellular immune responses were induced.
Fewer pneumococci were recovered from the nasopharynx of mice
immunized with chitosan-PsaA. Mucosal and systemic immune responses
were generated and ultimately prevented pneumococcal nasopharyngeal
colonization.
[153]
Chitosan-PsaA protein
The average size
of particle was 691
nm; zeta potential
was +21.1 mV
S. pneumoniae ATCC
6303 (serotype 3) PsaA
The systemic (IgG in serum) and mucosal (IgA in mucosal lavage) specific
antibodies were enhanced.
Protection against acute otitis media following middle ear challenge with
pneumococcus serotype 14 was increased
The survival rate of mice immunized with chitosan–PsaA nanoparticles in
an intraperitoneal challenge with pneumococcus serotype 3 or serotype 14
was improved.
[154]
Chitosan-PCV13 The particle size of46.1nm
PCV13; Prevnar®;
Pfizer Inc
No difference was observed in the level of total antibodies against Pn14PS
antigen in the mouse groups with or without adjuvant codelivery.
Both chitosan-PCV codelivery and Quil-A adjuvant (control) elicited IgG1,
IgG2a, IgG2b, and IgG3 antibodies.
[155]
Cationic liposomes
(DOTAP and DC-chol)
The particle size of
137.9 ± 11.6 nm;
Zeta potential of
4.0 ± 2.1 mV
n/a PspA, family 1 clade-2
Liposomes composed of 1,2-dioleoyl-3-trimethylammonium-propane
(DOTAP) and cholesteryl 3β-N- (dimethylaminoethyl)carbamate
(DC-chol) (DOTAP/DC-chol liposome).
Provideed protective immunity against lethal inhalation of S. pneumoniae,
and improved the survival rate of infected mice.
Intranasal immunization with DOTAP/DC-chol liposomes carrying PspA
induced both mucosal and systemic response.
PspA-specific Th17 response was elicited. It plays a pivotal role in
controlling S. pneumoniae infection by host innate immune response.
[156]
Gold nanoparticles
(GNPs)
Mean gold core of
1.8 ± 0.5 nm;
Average molecular
weight of 84 to 97
kDa.
n/a
S. pneumoniae type 14,
polysaccharide
(Pn14PS) conjugated
to CRM197
(Pn14PSCRM197), and
T-helper ovalbumin
323–339 peptide
(OVA323–339)
Specific anti-Pn14PS IgG antibodies were triggered.
T-helper cell activation was promoted by glyconanoparticles
The functionality of the antibodies was maintained as the antisaccharide
antibodies promoted the phagocytosis of type 14 bacteria by human
leukocytes.
[157]
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Table 2. Cont.
Nanoparticles Characteristics ofNanoparticles
Pneumococcal
Strains Used in
Challenge Studies
Antigen (s) Results References
Gold-glyco- nanoparticles
Mean gold core of
1.2 ± 0.3 nm;
Average molecular
weight of 45 to 55
kDa.
n/a
Serotype 14 (Tetra-14)
and serotype 19F
(Tri-19F), and a
T-helper ovalbumin
323–339 peptide
(OVAp)
A synthetic carbohydrate vaccine. GNPs functionalized with Pn19F and/or
Pn14 saccharide ligands.
The titers of specific IgG antibodies towards type 14 polysaccharide were
enhanced.
[158]
PspA-based
polyanhydride
The particle size of
50:50 CPTEG: CPH
455± 175; Zeta
potential of
−33.1± 5.1 mV
S. pneumoniae strain
A66.1(PspA family 1,
clade 2)
Pneumococcal surface
protein A (PspA)
A room temperature stable PspA-based polyanhydride nanovaccine
reduced the cost of vaccine care and transportation.
Single immunization of the mice with nanovaccine and upon challenge
presented significantly higher survival rates compared to mice immunized
with soluble protein alone.
A 25-fold reduction in protein dose of nanovaccine presented higher
survival rates in immunized mice compared to the PspA soluble protein.
A single dose of PspA-based nanovaccine against S. pneumoniae induced
protective immunity.
[161]
Lipoprotein n/a S. pneumoniae D39
MetQ, PnrA, PspA
and DacB proteins
High antibody titers were present in sera from mice immunized with the
lipoproteins MetQ, PnrA, PsaA, and DacB.Mice were immunized
intranasally with PnrA, DacB, and MetQ using cholera toxin subunit B
(CTB) as an adjuvant, followed by an intranasal challenge with S.
pneumoniae D39. No pneumococcal colonization was observed in
vaccination using PnrA while DacB and MetQ led to reduction of the
bacterial load.
The increased production of antigen-specific IL-17A in the nasal cavity
reduced bacteria colonization.
High systemic IgG levels were induced with a predominance for the IgG1
isotype, except for DacB.
[162]
~ 40 nm S. pneumoniae Rx1 PspA, family 1,clades 2
cCHP nanogel contained 20 amino groups per 100 glucose units.
Longer retention of PspA (in nanogel) was observed in the nasal cavity
when compared with the administration of PspA alone.
No deposition of [18F]-PspA was seen in the olfactory bulbs or brain.
PspA-specific serum IgG with protective activity and mucosal secretory
IgA (SIgA) Ab responses in cynomolgus macaques (Macaca fascicularis)
were induced.
[163]
Note: n/a: not available; PspA: pneumococcal surface protein A; MetQ: methionine binding protein; PnrA: pneumococcal nucleoside-binding protein; DacB: L,D-carboxypeptidase; PsaA:
pneumococcal surface adhesin A; cCHP: cationic cholesteryl group-bearing pullulan.
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Lipoproteins are highly conserved among S. pneumoniae and are highly immunogenic. Hence, they
can serve as a useful target for future vaccine development. Voß et al. immunized mice intranasally
with the recombinant proteins, pneumococcal nucleoside-binding protein (PnrA), methionine-binding
protein (MetQ), L,D-carboxypeptidase (DacB), and PsaA, using cholera toxin subunit B (CTB) as an
adjuvant. Following the intranasal challenge with S. pneumoniae D39, the PnrA lipoprotein vaccine
was able to prevent nasopharyngeal colonization. The protective effects of MetQ and DacB were
insignificant [162].
Meanwhile, nanogel, a safe and effective nanosize nasal vaccine delivery system based on cationic
cholesteryl group-bearing pullulan (cCHP) containing PspA was developed by Fukuyama et al. [163].
The colonization and invasion by pneumococcus in both the upper and lower respiratory tracts were
reduced and high levels of systemic and nasal mucosal Th17 responses were induced in the infected
airway of the cynomolgus macaques (Macaca fascicularis) model. The cCHP nanogel could potentially
be employed as an antigen-delivery carrier for adjuvant-free nasal vaccination for the prevention of
pneumonia in humans [69,163].
6. Conclusions
Streptococcus pneumoniae is responsible for non-invasive diseases such as acute otitis media and
sinusitis in the community, but infection can also lead to serious complications, such as meningitis and
septicemia. Mortality rates are high especially in the very young, elderly, and immunocompromised
individuals. Despite the success of the polysaccharide PPV23 and the conjugated PCV10/13 vaccines
to reduce pneumococcal infections, several issues remain, such as inadequate protection against
capsular serotypes, which are not included in the vaccine and the unencapsulated Streptococcus
pneumoniae (NESp). PPV23 has low immunogenicity and generates low immune memory response
in the very young. New PCV-based vaccines would require country- and serotype-specific antigens,
which could be changing continuously and placing limitations in making new PCV-based vaccines.
The live-attenuated whole-cell vaccine posed concern about reversion to pathogenicity, while the
inactivated whole-cell vaccine required multiple dosages and produced non-lasting humoral responses.
This study highlights the new approaches to design an effective pneumococcal vaccine.
A live-attenuated vaccine with low pathogenicity could be constructed by introducing multiple
mutations as well as deletions in the pneumococcal genome. For example, a mutant deficient in pep27
and comD genes with reduced transformation ability could be further mutated in virulence genes,
such as PspA, PsaA, PspC, and pneumolysin (Ply). The protein-based vaccines in early development
were based on the full-length protein, which had high sequence variability and differences in levels
of expression in different serotypes. The identification of highly conserved antigenic regions within
the virulence proteins enables the use of distinct protein fragments. This allows the construction of
combined antigenic regions represented by peptides. Due to the low immunogenicity of peptides, they
could be conjugated to Toll-like receptors (TLRs) or nanoparticles. Further design of protein-based
vaccines conferring serotype independent protection might be achieved through the development of
bacterium-like particles (BLPs) or microparticles/nanoparticles presenting multiple virulence surface
proteins such as PspA2 in combination with PspA4 and PsaA. BLPs displaying multiple antigens or
nanoparticles formulated with pneumococcal surface proteins looked like promising strategies for
mucosal immunization to enhance both systemic and mucosal immune responses.
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